Page 74 - Looking Statements News Today

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with three clinical programs in development and a strong...

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update

BOSTON, Feb. 28, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks , which is building the leading platform for cell programming and biosecurity, announced the acquisition of key assets of Reverie Labs,...

BOSTON, Feb. 28, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks , which is building the leading platform for cell programming and biosecurity, announced the acquisition of Proof Diagnostics, an...

Delivered 4.6% Organic Revenue Growth in 2023 Increased 2023 Net Income 25.9% to $135.7 Million, or $0.92 Per Diluted Share, with Adjusted EPS of $0.94 Achieved 2023 Adjusted EBITDA of $285.6...

Record Quarterly and Full-Year Revenues of $3.44 billion and $12.58 billion, respectively Record Quarterly and Full-Year Diluted EPS of $4.47 and $13.31, respectively Non-GAAP Full-Year Diluted...

-Record full year net revenues of $6.9 billion, representing approximately 6% and 5.5% reported and organic growth, respectively, with continued double-digit organic core inspection revenue...

Selection of assay results from Red Star epithermal Au-Ag project The Red Star project offers exceptional discovery potential for epithermal high-grade Ag-Au, polymetallic Ag-Au and wide low-grade gold-silver mineralization. ROUYN-NORANDA, Quebec, Feb. 28, 2024 (GLOBE NEWSWIRE) -- GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz, LS Exchange, TTMzero, Düsseldorf and Quotrix Düsseldorf...

IGC Pharma, Inc. today announced the results of preclinical studies investigating its drug candidate TGR-63 as a treatment for Alzheimers disease. The data demonstrated enhanced memory function in...

Full year subscription revenue grew 13% year-over-year, 15% on a constant currency basis ...